Industry

2025.11.05 Jackson Lin

Global IP Insights Converge for Innovation Growth Opportunities WISPRO was honored to welcome representatives from the UK-based intellectual property law firm Withers & Rogers LLP for an in-depth exchange on IP strategies and global partnership opportunities. Howard Wright (Partner) and Hendrik Bahre (Senior Associate) visited WISPRO’s New Taipei City office, where the teams engaged in a comprehensive discussion covering patent and trademark prosecution practices, SEP development, and collaborative content strategies tailored for high-potential markets. Collaborative Strategies for Global Visibility Beyond technical collaboration, WISPRO and Withers & Rogers explored opportunities for joint branding and thought leadership initiatives, including webinars and other...

2025.10.27

This month, WISPRO had the pleasure of welcoming long-time partner firm MUELLER HOFFMANN & PARTNER Patentanwälte mbB to our new office for the first time. Over the years, we’ve worked closely with their team on numerous IP matters—often in daily contact—and this in-person visit marked a new chapter in our collaboration. Valuable Insights on EPO Appeal Proceedings During their visit, European Patent and Trademark Attorneys Dr. Nils Jensen and Dr. Johannes Held generously delivered an exclusive session on “Appeal Proceedings before the European Patent Office (EPO)”. Their hands-on experience provided our team a detailed overview of procedural nuances, strategic considerations,...

2025.10.22 Jackson Lin

Authored by Jackson Lin, CEO of Wispro Technology Consulting Corporation and IXI MedTech Team. Summary: This quarterly report analyzes every Class II 510(k) clearance issued by the U.S. FDA in Q3 2025. Using IXI MedTech’s intelligence platform, it reveals trends in applicant behavior, review-time efficiency, and the creation of new product codes — showing how regulatory learning and data-driven insight shape MedTech competitiveness. Keywords: FDA 510(k) | Class II | Medical Device Regulation | Review Time | New Product Codes | MedTech Intelligence | Regulatory Trends Executive Summary Volume steady, signal sharper. Q3 2025 saw 753 clearances from 595 applicants...

2025.10.03

Dear 3GPP experts and friends, Thank you for being an essential part of the Standard Impact Extractor (SIE) journey and for the generous feedback you’ve shared with us. After careful evaluation, we have made the decision to discontinue the free online services of the SIE — including TDoc Explorer, TDoc Viewer, and Proposal Zone — effective September 4, 2025. Our deep appreciation to the 3GPP community. Your usage, comments, and critiques were invaluable. They helped us test ideas quickly and learn what matters most in real-world standardization workflows. Looking ahead to 6G As 2025 marks a critical beginning for the 6G standardization cycle, we wish the 3GPP community...

2025.10.01

Dear Valued Clients and Partners, Thank you for your continued trust and support. To accommodate our growing business needs, we are pleased to announce that our office will be relocating to a new address starting Monday, October 13, 2025. For all future business correspondence, inquiries, payment notifications, and communications, please update your records with the following information. We apologize for any inconvenience this may cause. We sincerely look forward to continuing our partnership with you and achieving greater success together. New Address: 7F, No. 226, Section 3, Zhonghua Road, Xinzhuang District, New Taipei City 242, Taiwan Phone (Unchanged): +886-2-2656-1168 ;...

2025.07.16 Jackson Lin

The U.S. FDA 510(k) clearance data from the second quarter of 2025 provides critical insights into the development of the global digital health industry. This analysis focuses on the market opportunities and competitive realities revealed by this quarter's data, aiming to offer a strategic reference for MedTech companies, startups, and investment institutions. Key Takeaways Market Focus: AI imaging software (QIH) has become the most popular FDA 510(k) regulatory pathway in Q2 2025, with 24 clearances. Competitive Barrier: The key barrier to entry is "regulatory experience." "Expert-level" players with 6+ historical clearances dominate nearly 45% of the market. Efficiency Gap: Expert-level...

2025.06.26 Jackson Lin

  As the dust settles from RAN#108 in Prague, the industry now has the approved 6G Study Item (RP-251881)—the first concrete blueprint for the next generation of wireless. While it's easy to focus on the individual technical objectives, a deeper look reveals a crucial strategic pivot that will define the success of our contributions for the next decade. The core insight from Wispro's analysis is this: The final 6G Study Item reveals a deliberate pivot from a collection of siloed features to a single, unified design philosophy that prioritizes long-term simplicity and harmonization. Here’s what that means for the 3GPP...

2025.06.17

Global Recognition from a Leading IP Authority The IAM Patent 1000 is a globally trusted and authoritative guide for companies seeking top-tier patent services. As one of the most prestigious annual rankings in the intellectual property industry, it is compiled by the team at Intellectual Asset Management through months of in-depth interviews and market analysis, covering over 50 jurisdictions worldwide. Being listed in this guide signifies exceptional recognition for a firm’s professional capabilities, service quality, and client trust on the global stage.   Dual Recognition Underscores Wispro’s IP Strategy Leadership WISPRO Technology Consulting Corporation makes its debut in the 2025...